Rink Amide-MBHA Resin
目录号 : GA10925肽酰胺的 SPS
Cas No.:431041-83-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Rink Amide-MBHA resin is less acid sensitive than Rink Amide resin since the benzhydrylamine linker is joined to the support through an electron-withdrawing acetamido spacer. Usually the products are detached from the resin using 95%TFA in DCM and scavengers required by the substrate composition. In addition, Rink Amide-MBHA resin is also useful for peptide syntheses. Previous study has recently reported the syntheses of tri-, tetra- and pentapeptides via a solid phase synthesis methodology by using a Rink Amide MBHA resin[1].
Rink Amide-MBHA resin: 4-(2',4'-Dimethoxypheyl-Fmoc-aminomethyl-phenoxy-acetamido- norleucyl-MBHA resin; Substitution: 0.4 - 0.8 mmole/g resin; Bead size 100- 200 mesh (polystyrene- 1% DVB)
Structure:Appication: Using the Rink Amide MBHA resin and a Fmoc strategy giving C-terminal amide form peptides, substituted benzhydrylamine and benzylamine linkage agents useful for the solid phase peptide synthesis were evaluated for their relative lability toward trifluoroacetic acid. The two most reactive linkage agents studied were compared in the synthesis of two different peptide amides by the N α-9-fluorenylmethyloxycarbonyl protecting group strategy [2].
Reference:
[1] Boussard C, Doyle VE, Mahmood N, Klimkait T, Pritchard M, Gilbert IH. Design, synthesis and evaluation of peptide libraries as potential anti-HIV compounds, via inhibition of gp120/cell membrane interactions, using the gp120/cd4/fab17 crystal structure. Eur J Med Chem. 2002;37(11):883-90.
[2] Michael S. Bernatowicz, Scott B. Daniels, Hubert Köster. A comparison of acid labile linkage agents for the synthesis of peptide C-terminal amides. Tetrahedron Letters Volume 30, Issue 35, 1989, Pages 4645–4648
Cas No. | 431041-83-7 | SDF | |
分子式 | 100-200:mesh,1%DVB | 分子量 | 0.3~0.8mmol/g |
溶解度 | 储存条件 | Store at -20°C | |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3333.3333 mL | 16666.6667 mL | 33333.3333 mL |
5 mM | 666.6667 mL | 3333.3333 mL | 6666.6667 mL |
10 mM | 333.3333 mL | 1666.6667 mL | 3333.3333 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。